Australia markets close in 5 hours 41 minutes
  • ALL ORDS

    7,550.50
    -36.90 (-0.49%)
     
  • ASX 200

    7,223.50
    -32.50 (-0.45%)
     
  • AUD/USD

    0.7127
    -0.0015 (-0.21%)
     
  • OIL

    67.02
    +0.84 (+1.27%)
     
  • GOLD

    1,776.60
    +0.10 (+0.01%)
     
  • BTC-AUD

    80,454.29
    -1,551.09 (-1.89%)
     
  • CMC Crypto 200

    1,456.40
    +13.62 (+0.94%)
     
  • AUD/EUR

    0.6283
    -0.0039 (-0.62%)
     
  • AUD/NZD

    1.0439
    -0.0022 (-0.21%)
     
  • NZX 50

    12,687.88
    -31.03 (-0.24%)
     
  • NASDAQ

    16,135.92
    -263.32 (-1.61%)
     
  • FTSE

    7,059.45
    -50.50 (-0.71%)
     
  • Dow Jones

    34,483.72
    -652.22 (-1.86%)
     
  • DAX

    15,100.13
    -180.73 (-1.18%)
     
  • Hang Seng

    23,475.26
    -376.98 (-1.58%)
     
  • NIKKEI 225

    27,821.76
    -462.16 (-1.63%)
     

Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine

·4-min read
Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting